# Third Teeth

> Tooth regeneration, on the record.

Third Teeth is an independent, dated, non-commercial evidence publication on tooth regeneration (the "third dentition" field). It aggregates, dates, and grades the public record; it does not conduct research. The dataset is released under CC BY 4.0 with attribution to the cited primary sources. Machine-readable export: https://thirdteeth.com/data/programs.json

## State of the field

- [Current pass, written 2026-07-28](https://thirdteeth.com/field/): every tracked programme tiered T1-T5 against the cited record.
- [Pass archive](https://thirdteeth.com/field/passes/): superseded passes, append-only, never edited.

## Programmes

- [Anti-USAG-1 antibody (TRG-035)](https://thirdteeth.com/programs/anti-usag-1-trg035/): Toregem BioPharma / Kyoto University; route whole-tooth; tier T4 (Human efficacy or safety, single programme).
- [Pulp and dentine repair (DPSC/SHED grafts, small molecules)](https://thirdteeth.com/programs/pulp-dentin-repair/): Multiple academic groups (Xuan et al. autologous pulp stem cell trial; Sharpe lab GSK-3 antagonist work); route repair; tier T3 (Small or narrow human data).
- [Bioengineered tooth germ (organ germ transplant)](https://thirdteeth.com/programs/bioengineered-tooth-germ/): Tsuji lab lineage (Ikeda et al., RIKEN / Tokyo University of Science); route whole-tooth; tier T2 (Animal result).
- [Dental epithelial organoids](https://thirdteeth.com/programs/epithelial-organoids/): Academic laboratories (e.g. Hemeryck et al., KU Leuven / UHasselt); route component; tier T2 (Animal result).
- [Tooth root organoids / whole-tooth reassociation](https://thirdteeth.com/programs/root-organoids/): Academic laboratories (e.g. Syed-Picard lab, University of Pittsburgh); route component; tier T2 (Animal result).

## Ledger

- 2009-08-03 · Functional bioengineered tooth replacement in an adult mouse (programme: bioengineered-tooth-germ)
- 2021-02-12 · Anti-USAG-1 antibody rescues tooth agenesis in mouse models (Science Advances) (programme: anti-usag-1-trg035)
- 2024-05-03 · Phase I first-in-human study of TRG-035 announced and registered (Kitano Hospital) (programme: anti-usag-1-trg035)
- 2025-09-29 · TRG-035 receives Japanese orphan drug designation for severe congenital partial anodontia (programme: anti-usag-1-trg035)
- 2026-05-19 · Sponsor reports Phase I dosing complete; Pre-Series C financing disclosed for Phase II (programme: anti-usag-1-trg035)

## Analysis

- [What the TRG-035 Phase I record actually establishes](https://thirdteeth.com/analysis/anti-usag-1-phase-one-record/): The Phase I record shows a single ascending dose tolerated in adults. It says nothing about growing teeth in anyone, and the Phase II population is children with congenital agenesis, not adults.

## Reference pages
- [Method & tier definitions](https://thirdteeth.com/method/)
- [Glossary](https://thirdteeth.com/glossary/)
- [Sources & bibliography](https://thirdteeth.com/sources/)
- [About](https://thirdteeth.com/about/)